Costa rica launches registry to monitor new psoriasis drugs in real life
NCT ID NCT07448402
First seen Mar 10, 2026 · Last updated May 13, 2026 · Updated 7 times
Summary
This study will follow 50 people in Costa Rica who are already taking IL-23 inhibitors (guselkumab or risankizumab) for psoriasis or psoriatic arthritis. Researchers will track how well the drugs control skin and joint symptoms and improve quality of life, as well as any side effects. The goal is to see how these treatments work in everyday medical practice, not just in controlled trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Caja Costarricense del Seguro Social
San José, Provincia de San José, 40901, Costa Rica
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.